Dept. of Counseling, University of Texas Rio Grande Valley, 1201 W. University Dr., Edinburg, TX 78539, United States.
Dept. of Psychology, John F. Kennedy University, Orinda, CA, United States.
Conscious Cogn. 2018 Aug;63:74-88. doi: 10.1016/j.concog.2018.05.012. Epub 2018 Jun 27.
An experimental home study examined the impact of a pre-sleep protocol for enhancing self-awareness, lucidity, and responsiveness in dreams. It included ingesting the cholinesterase inhibitor galantamine--which is widely reported to increase the frequency of lucid dreaming--prior to engaging in middle-of-the-night meditation and the imaginary reliving of a distressing dream while exercising new responses. Thirty-five participants completed an eight-night study, which included pre- and post-baseline nights and six conditions: waking for 40 min before returning to bed, called Wake-Back-to-Bed (WBTB); Wake-Back-to-Bed plus placebo (WBTB + P); Wake-Back-to-Bed plus galantamine (WBTB + G); meditation and dream reliving (MDR); meditation and dream reliving plus placebo (MDR + P); and meditation and dream reliving plus galantamine (MDR + G). The outcome measures included lucidity, reflectiveness, interactive behavior, role change, constructive action, and fear and threat, as measured by the participants' self-ratings. The results support the use of this protocol in further studies of lucid dream induction and nightmare/trauma resolution.
一项实验性家庭研究考察了睡前自我意识增强、清醒和梦境反应性的预睡眠方案的影响。该方案包括在夜间中段进行冥想和想象性地重温痛苦的梦的同时，摄入广泛报道可增加清醒梦频率的胆碱酯酶抑制剂加兰他敏，并采用新的反应。35 名参与者完成了一项为期八晚的研究，其中包括基线前和基线后的夜晚，以及六种条件：醒来 40 分钟后再回到床上，称为 WBTB（醒来后回到床上）；WBTB 加安慰剂（WBTB+P）；WBTB 加加兰他敏（WBTB+G）；冥想和梦的再体验（MDR）；冥想和梦的再体验加安慰剂（MDR+P）；以及冥想和梦的再体验加加兰他敏（MDR+G）。结果指标包括清醒度、反思性、互动行为、角色转换、建设性行动，以及参与者自我评估的恐惧和威胁。研究结果支持进一步研究清醒梦诱导和噩梦/创伤解决时使用该方案。
